PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24103422-0 2013 Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-xL inhibitors on human ovarian carcinoma cells. Citric Acid 34-41 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 14-19 27912843-5 2016 Strategies aiming to increase cytosolic citrate should be developed and tested in humans, knowing that experimental studies have shown that administration of citrate and/or inhibition of ACLY arrest tumor growth, inhibit the expression of the key anti-apoptotic factor Mcl-1, reverse cell dedifferentiation and increase sensibility to cisplatin. Citric Acid 158-165 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 269-274 24103422-2 2013 We have studied their concomitant inhibition, using ABT 737 or siRNA targeting XL1 and citrate, a molecule which reduces the expression level of Mcl-1.Two cisplatin-chemoresistant ovarian cell lines (SKOV3 and IGROV1-R10) were exposed to ABT 737 or siRNA targeting XL1 and citrate at various individual concentrations, or combined. Citric Acid 87-94 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 145-150 24103422-4 2013 Western blot analyses were performed to detect various proteins implied in apoptotic cell death pathways.Mcl-1 expression was barely reduced when cells were exposed to citrate alone, whereas a mild reduction was observed after ABT 737 treatment. Citric Acid 168-175 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 105-110 24103422-5 2013 Concomitant inhibition of Bcl-xL and Mcl-1 using ABT 737 or siXL1 associated with citrate was far more effective in inhibiting cell proliferation and inducing cell death than treatment alone.Given that few, if any, specific inhibitors of Mcl-1 are currently available, anti-glycolytic agents such as citrate could be tested in association with synthetic inhibitors of Bcl-xL. Citric Acid 82-89 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 37-42 24103422-5 2013 Concomitant inhibition of Bcl-xL and Mcl-1 using ABT 737 or siXL1 associated with citrate was far more effective in inhibiting cell proliferation and inducing cell death than treatment alone.Given that few, if any, specific inhibitors of Mcl-1 are currently available, anti-glycolytic agents such as citrate could be tested in association with synthetic inhibitors of Bcl-xL. Citric Acid 82-89 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 238-243 24103422-5 2013 Concomitant inhibition of Bcl-xL and Mcl-1 using ABT 737 or siXL1 associated with citrate was far more effective in inhibiting cell proliferation and inducing cell death than treatment alone.Given that few, if any, specific inhibitors of Mcl-1 are currently available, anti-glycolytic agents such as citrate could be tested in association with synthetic inhibitors of Bcl-xL. Citric Acid 300-307 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 37-42 21498699-7 2011 RESULTS: A 3-day continuous exposure to citrate led to near destruction of the cell population in both cell lines, apoptotic cell death occurred through the mitochondrial pathway in a dose- and time-dependent manner, associated with the reduction of the anti-apoptotic Mcl-1 protein in both lines. Citric Acid 40-47 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 269-274 21498699-8 2011 CONCLUSION: Citrate demonstrates strong cytotoxic activity against two gastric cancer lines, leading to an early diminution of expression of Mcl-1 and to massive apoptotic cell death involving the mitochondrial pathway. Citric Acid 12-19 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 141-146 19414371-3 2009 RESULTS: A 3-day continuous exposure to citrate led to apoptotic cell death via a mitochondrial pathway, associated with a reduction of anti-apoptotic protein Bcl-x(L) and Mcl-1 expression. Citric Acid 40-47 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 172-177 35626081-11 2022 Consistently, in various cultured cancer cells (including melanoma, sarcoma, hematologic, and epithelial cancer cells), this "citrate strategy" efficiently inhibits the IGFR1/AKT pathway, promotes PTEN activity, reduces Bcl-xL and MCL1 expression, and increases sensitivity to standard chemotherapy. Citric Acid 126-133 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 231-235